CAMBRIDGE, Mass. and NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: 23rd Annual Needham Virtual Healthcare Conference presentation at 8:00am ET on Wednesday ...

Shares of Black Diamond (BDTX) have gained 20.5% over the past four weeks to close the last trading session at $5.41, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $10.60 indicates a potential upside of 95.9%.The mean estimate comprises five short-term price targets with a standard deviation of $0.89. While the lowest estimate of $10 indicates an 84.8% increase from the curren ...

Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCClinical data on track for Q3 2024 in Phase 2 trial of BDTX-1535 in 2L/3L patients with acquired resistance or non-classical EGFRm NSCLC Oral presentation at AACR annual meeting in April 2024 describing real world evidence of an evolving EGFR mutation landscape in NSCLC, and the potential of BDTX-1535 to benefit patients across multiple lines of therapy Additional planned data releases for 2024 include GBM results ...

On November 30, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-ofsale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal an ...

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC • Clinical data on track for Q3 2024 in Phase 2 trial of BDTX-1535 in 2L/3L patients with acquired resistance or non-classical EGFRm NSCLC • Additional planned data releases for 2024 include GBM results for BDTX-1535 in Q2, and initial results for BDTX-4933 in non-G12C KRASm NSCLC in Q4 • Cash, c ...

CIPhotos Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is a precision oncology company targeting genetically defined cancers. It calls its approach the Masterkey approach, which aims to provide one solution for many types of cancer mutations and address the disease in a much broader range of patients than current precision therapies can access. Its oral therapies are designed to target families of oncogenic mutations including drug-resistant mutations, and are also designed to cross the blood-brain bar ...

SECURITIES AND EXCHANGE COMMISSION | --- | --- | --- | |---------------------------------------------------------------------------------------|---------------------------------------|-------------------------------------------------------| | Securities registered pursuant to Section 12(b) \nTitle of each class | of the Act: \nTrading Symbol(s) | Name of each exchange on which registered | | Common stock, par value $0.0001 | BDTX | The Nasdaq Global Select Market | Non-accelerated filer ☒ Smaller reporting ...

During the six months ended June 30, 2023, we had cash provided by financing activities of $0.1 million, consisting of proceeds from the participation in the employee stock purchase plan. During the six months ended June 30, 2022, we had cash provided by financing activities of $0.2 million consisting of proceeds from exercise of stock options and participation in the employee stock purchase plan. | --- | --- | --- | --- | --- | |--------------------------------------------------------------------|-------|- ...

• the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the U.S. Food and Drug Administration (FDA) and non-U.S. regulators; • the extent of any required post-marketing approval commitments to applicable regulatory authorities; • development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch; General and administrative Other income was $0.7 million for the three mon ...

• our estimates regarding the market opportunities for our product candidates, including our competitive position and the success of competing therapies that are or may become available; • our need for and ability to attract and retain key scientific, management and other personnel and to identify, hire and retain additional qualified professionals; Table of Contents PART I Approved targeted therapies, such as kinase inhibitors, have transformed the treatment of cancers and demonstrated a significant benefi ...